(HealthDay News) — The oral small-molecule glucagon-like peptide 1 (GLP-1) receptor agonist orforglipron demonstrates superior weight loss as an adjunct to lifestyle modification versus placebo for ...

PSMAddition is an international, open-label, prospective, phase 3 randomized controlled trial of 177Lu-PSMA-617 plus ADT and ARPI in PSMA-positive mHSPC.

Having a longer travel time to their treatment facility improves survival in prostate cancer patients, according to a recent study.

No significant differences in mean cost of care or in 30-day readmission for home hospital versus brick-and-mortar hospital care.

(HealthDay News) — Most speakers attending U.S. Food and Drug Administration (FDA) Human Drug Advisory Committee meetings about new drugs or indications support approval, according to a research ...

“We need organizational strength and stability at the agency,” John Crowley, CEO of the biotechnology trade group BIO, told STAT News. “This constant turmoil is undermining America’s leadership in ...

A study has found a link between exposure to heatwaves and higher ambient temperatures and increased risk of cardiovascular mortality.

In this meta-analysis, researchers evaluated the use and/or prolongation of ADT in men with non-metastatic prostate cancer undergoing definitive radiotherapy. For men with prostate cancer treated with ...

(HealthDay News) — Abdominal obesity is associated with more harmful changes to heart structure than body weight alone, according to a study presented at the annual meeting of the Radiological Society ...

(HealthDay News) — For patients with type 2 diabetes, there is an association between glucagon-like peptide-1 receptor agonist (GLP-1 RA) use and chronic cough, according to a study published online ...

Increases in levels of blood biomarkers of Alzheimer disease seen over time for all participants, with faster rates of increase for individuals with obesity.

Investigators reported 1-year disease-free survival results from patients with BCG-unresponsive papillary disease-only high-risk NMIBC in the phase 2b SunRISe-1 trial.